Application of luteinizing hormone-releasing hormone–ferrosoferric oxide nanoparticles in targeted imaging of breast tumors

Nian, Di; Shi, Peng; Sun, Jie; Ren, Li; Xiao-na, Hao; Han, Junwei

doi:10.1177/0300060519834457

Cited by 14 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same group also determined that the entrance of GnRH-MNPs to TBNC cells depends on its high efficiency to bind to the GnRH-R ( 119 ), suggesting that GnRH-MNPs can be used for the specific targeting of TNBC cells for both cancer detection and treatment. Similar conclusions were found by Nian et al ( 81 ), who synthetized GnRH-ferrosoferric oxide (GnRH-Fe 3 O 4 ) nanoparticles. This formulation showed higher concentrations in the tumor (under the effect of a magnetic field in vivo , and most importantly, without evidence of heart, liver, or lung toxicity ( 81 ).…”

Section: Gnrh-based Nano-formulations In Breast Cancersupporting

confidence: 88%

Conventional and new proposals of GnRH therapy for ovarian, breast, and prostatic cancers

et al. 2023

View full text Add to dashboard Cite

For many years, luteinizing hormone-releasing hormone or gonadotropin-releasing hormone (GnRH) analogs have been used to treat androgen or estrogen-dependent tumors. However, emerging evidence shows that the GnRH receptor (GnRH-R) is overexpressed in several cancer cells, including ovarian, endometrial, and prostate cancer cells, suggesting that GnRH analogs could exert direct antitumoral actions in tumoral tissues that express GnRH-R. Another recent approach based on this knowledge was the use of GnRH peptides for developing specific targeted therapies, improving the delivery and accumulation of drugs in tumoral cells, and decreasing most side effects of current treatments. In this review, we discuss the conventional uses of GnRH analogs, together with the recent advances in GnRH-based drug delivery for ovarian, breast, and prostatic cancer cells.

show abstract

Section: Gnrh-based Nano-formulations In Breast Cancersupporting

confidence: 88%

Conventional and new proposals of GnRH therapy for ovarian, breast, and prostatic cancers

et al. 2023

View full text Add to dashboard Cite

show abstract

“…There is there an urgent need to design novel chemokine inhibitors that do not disturb the function of healthy cells. A number of LHRH receptors have been found in breast, ovarian and prostate cancer, but their expression is low or absent in the corresponding healthy tissues [ 106 , 107 ]. Therefore, several nanoplatforms modified with LHRH peptides have been explored for the targeted delivery of therapeutic agents [ 108 – 111 ].…”

Section: Receptor-mediated Active Targeting Strategymentioning

confidence: 99%

Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies

et al. 2022

View full text Add to dashboard Cite

Poor targeting of therapeutics leading to severe adverse effects on normal tissues is considered one of the obstacles in cancer therapy. To help overcome this, nanoscale drug delivery systems have provided an alternative avenue for improving the therapeutic potential of various agents and bioactive molecules through the enhanced permeability and retention (EPR) effect. Nanosystems with cancer-targeted ligands can achieve effective delivery to the tumor cells utilizing cell surface-specific receptors, the tumor vasculature and antigens with high accuracy and affinity. Additionally, stimuli-responsive nanoplatforms have also been considered as a promising and effective targeting strategy against tumors, as these nanoplatforms maintain their stealth feature under normal conditions, but upon homing in on cancerous lesions or their microenvironment, are responsive and release their cargoes. In this review, we comprehensively summarize the field of active targeting drug delivery systems and a number of stimuli-responsive release studies in the context of emerging nanoplatform development, and also discuss how this knowledge can contribute to further improvements in clinical practice.

show abstract

“…Targeted nanoparticles delivered significantly more iron particles to MCF-7 cells than non-targeted nanoparticles. Targeted nanoparticles showed timedependent accumulation in tumor tissues in animals under magnetic field (Nian et al 2019).…”

Section: Gnrh-imaging Agent Conjugates For Diagnostic Applicationsmentioning

confidence: 99%

New drug delivery strategies targeting the GnRH receptor in breast and other cancers

Ghaly

Varamini

2021

Endocrine-Related Cancer

View full text Add to dashboard Cite

Cancer is the uncontrolled division of abnormal cells in a specific organ. Globally, about 1 in 6 deaths is due to cancer. Despite the plethora of research being undertaken worldwide to find a cure for cancer, it remains a significant challenge. Cancer targeting via agents designed to interfere with some specifically or highly expressed molecules in cancer cells has been a shift in the treatment of various forms of cancers. The development of drug delivery systems, specifically to cancer cells, is a common approach that succeeded in increasing the efficacy and reducing the side effects of different anticancer agents. Gonadotropin-releasing hormone (GnRH) is a naturally occurring hormone with receptors overexpressed in many types of cancers related or unrelated to the reproductive system. Several drug delivery systems were developed using GnRH derivatives as targeting agents. In this review, we first discuss the role of GnRH and its receptors in cancer. Then, we provide a detailed insight into different delivery systems developed using GnRH derivatives as targeting agents in various types of GnRH receptor overexpressing cancers. Some promising findings from these studies indicate that GnRH receptor targeting is a potential strategy to efficiently guide anticancer therapeutics, diagnostic agents, and nucleic acids directly to cancer cells. Lastly, some limitations of the current research and suggestions for more successful outcomes in clinical trials of these delivery systems are highlighted.

show abstract

Application of luteinizing hormone-releasing hormone–ferrosoferric oxide nanoparticles in targeted imaging of breast tumors

Cited by 14 publications

References 18 publications

Conventional and new proposals of GnRH therapy for ovarian, breast, and prostatic cancers

Conventional and new proposals of GnRH therapy for ovarian, breast, and prostatic cancers

Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies

New drug delivery strategies targeting the GnRH receptor in breast and other cancers

Contact Info

Product

Resources

About